Tomorrow at #ESMO26#: MSK sarcoma medical oncologist Dr. Lauren Banks will present research on lifileucel in undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. 🗓️ Monday, October 26 | 9:34 a.m. CET

Tomorrow at #ESMO26#: MSK gastrointestinal medical oncologist @AndreaCercek will present the first results from the global AZUR1 trial of dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer. 🗓️ Sunday, October 25 | 11:00 a.m. CET

Today at #ESMO26#: Research co-authored by MSK gastrointestinal medical oncologist Dr. Yelena Janjigian will be presented from CLARITY-Gastric 01, a phase 3 study of sonesitatug vedotin in second- or later-line advanced or metastatic Claudin 18.2-positive gastroesophageal carcinoma. 🗓️ Sunday, October 25 | 5:18 p.m. CET

Surgical oncology evidence belongs to every physician treating cancer. The medical oncologist sequencing therapy needs to know what's resectable. The radiation oncologist planning a course needs to know what margins were achieved. The primary care physician explaining options to a newly diagnosed patient needs to know what surgical care actually involves. Today we're partnering with the Society of Surgical Oncology to bring @SocSurgOnc clinical content and educational resources into OpenEvidence. The partnership also launches the SSO Innovator Grant, a 24-month research award supporting surgeon-led work on AI-enabled medical knowledge and clinical decision support in surgical oncology. Applications open Summer 2026. The body of evidence in surgical oncology is growing faster than any single surgeon can track. The point of the partnership is to put that evidence in front of every physician taking care of a cancer patient, in the moment they need it.